San Francisco - The majority of current treatments for bullous pemphigoid (BP) are not supported by evidence from solid randomized controlled trials, according to Emory University researcher Seaver L. Soon, M.D.
Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
5 Perspectives on Laser Treatment in Dermatology
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Adel Haque, MD, Provides His Best Advice for New Dermatologists
Recent Povorcitinib 2b Study Shows Improved Repigmentation